Overview

This trial is active, not recruiting.

Condition cocaine-related disorders
Treatment quetiapine
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date October 2003
Trial size 12 participants
Trial identifier NCT00087750, NIDA-MDS-0001-1

Summary

The purpose of this study is to assess the safety of intravenous (IV) cocaine in subjects taking quetiapine at 3 dosage levels.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Masking double-blind
Primary purpose treatment

Primary Outcomes

Measure
Adverse events
time frame:
pharmacokinetic assessment
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: Includes but is not limited to: non-treatment seeking individuals. Must meet DSM-IV criteria for cocaine abuse or dependence. Must be able to verbalize understanding of consent and provide written informed consent and verbalize willingness to complete study procedures. Site will provide further details. Exclusion Criteria: Please contact site for further information

Additional Information

Official title Interaction Between IV Cocaine and Quetiapine
Principal investigator Domenic Ciraulo, M.D.
Description A placebo-controlled, double-blind, inpatient assessment of interaction between intravenous cocaine and quetiapine (seroquel) in cocaine-experienced subjects. To assess the safety of IV cocaine in subjects taking quetiapine at 3 dosage levels.
Trial information was received from ClinicalTrials.gov and was last updated in February 2007.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).